sST2 vs NT-proBNP: Which Cardiac Marker for Which Question

Updated 2026-09-28

Two cardiac markers that answer different questions — and why the choice changes what you should look for in the reagent.

Different biology, different question

sST2 is the soluble decoy receptor of IL-33 and reflects cardiac stress, fibrosis and remodelling. NT-proBNP is the N-terminal fragment released by ventricular myocytes under wall stress and volume load. One tells you what the myocardium is doing; the other tells you how hard it is working.

When each is the better readout

If your question concerns the IL-33/ST2 axis, fibrosis or remodelling, sST2 is the direct readout. For volume load and heart-failure assessment, NT-proBNP is conventional. Many groups measure both, because sST2 carries prognostic information independently of the natriuretic peptides.

What this means for reagent choice

The two targets have different manufacturing realities. Circulating NT-proBNP is O-glycosylated, and that glycosylation is a recognised source of variation between immunoassay methods; a recombinant standard expressed in E. coli is not glycosylated, which is precisely why epitope choice has to avoid the central region. sST2 is likewise a glycosylated protein, where the expression system and correct folding matter directly for binding activity. Choose the grade by target biology, not by price.

What the comparative studies actually found

The two markers were not developed against each other, and the comparative literature is more nuanced than a ranking would suggest. In the PRIDE cohort, ST2 measured at presentation in acute dyspnoea carried prognostic information, and the marker's value has since been shown to be at least partly independent of the natriuretic peptides — which is the finding that made measuring both defensible rather than redundant. Prognostic studies in acute and chronic heart failure, and a meta-analysis across chronic heart failure cohorts, support sST2 as a risk marker in its own right. The natriuretic peptides meanwhile retain their position for diagnosis and rule-out, where their sensitivity to ventricular wall stress and volume load is the property being used deliberately. The two answer different questions, and the literature reflects two different bodies of evidence rather than one contested ranking.

The analytical asymmetry that decides your assay design

There is an asymmetry between the targets that matters long before any clinical argument does. The natriuretic peptide field has lived with a glycosylation problem for two decades: circulating proBNP-derived fragments carry O-linked glycosylation, and antibodies directed at epitopes near a glycosylation site can show reduced recognition — a documented source of disagreement between methods, and the reason epitope placement in the central region of NT-proBNP is avoided. sST2 presents a different profile: the analytical risk sits in lot consistency and in the conformation of the recombinant material rather than in a variable modification of the circulating analyte. If you are choosing which assay to develop rather than which to buy, that difference in analytical risk belongs in the decision alongside the clinical question.

Ask a technical question